Entity

Eli Lilly

U.S. pharma major behind Mounjaro and Zepbound — the biggest beneficiary of the obesity-drug boom.

As of 8 Oct 2026Last evidence 7 Oct 2026

What is happening now

  • With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL

    Reported claim · first reported 3 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

All 1 event and claims involving Eli Lilly

What changed

  • Attention Eli Lilly has 53 mentions in tracked coverage: too few to measure a trend.
  • State Changes between snapshots: cannot measure, no state history is kept for Eli Lilly yet.
  • Claims No claim first reported since 7 Oct 2026.

How well we know this

276 documents · 89 publishers · 28% contain a typed assertion · last evidence 7 Oct 2026

  • Gap: assertion coverage 0.283: about 72% of mentions carry no typed assertion

In this snapshot’s daily coverage:

Reported alongside Eli Lilly

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

GLP-1AINovo NordiskTrumpUnited StatesChinaZepbound
  • GLP-1 · 89 shared documents
  • FDA · 79 shared documents · no page of its own yet
  • AI · 73 shared documents
  • Novo Nordisk · 50 shared documents
  • Trump · 42 shared documents
  • United States · 39 shared documents
  • China · 37 shared documents
  • Zepbound · 37 shared documents
  • Novartis · 34 shared documents · no page of its own yet
  • Amgen · 33 shared documents · no page of its own yet

Eli Lilly has 53 mentions in tracked coverage. That is too few to measure a trend. Watch Eli Lilly to hear when coverage grows, or request deeper coverage of Eli Lilly.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/85a46c3fe31041288a0a56c9 returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name eli lilly.

{
  "name": "eli lilly",
  "label": "Eli Lilly",
  "asOf": "2026-10-08",
  "mentions": 53,
  "outlets": 21,
  "domains": 4,
  "node": {
    "id": "sb:e/85a46c3fe31041288a0a56c9",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/85a46c3fe31041288a0a56c9",
    "knowledgeCutoff": "2026-10-08T20:34:57.810068+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "too few mentions to measure",
  "whereFrom": {
    "level": "counts",
    "label": "53 mentions across 4 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "4 coverage domains",
        "children": {
          "count": 4,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 47 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving Eli Lilly

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL

    Reported claim · first reported 3 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

    corroborated

Walk the record from Eli Lilly

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

Eli Lilly

Entity.

Evidence
276 documents · 89 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 6 May 2026, last seen 7 Oct 2026
Measured
28% of mentions say something specific about it; the rest only name it
As of
8 Oct 2026
11 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (1)

  • Reported by two: Reported by two sources that did not copy each other.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names Eli Lilly, newest first. Open any row to follow it to the original article. Sparse topics can mix unrelated senses of the word.

Evidence tiers: primary source = an official public record · attributed = a named outlet, receipt linked · lead = observed, not yet receipted.

Ask about Eli LillyWatch Eli Lilly

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 8 Oct 2026.